-
公开(公告)号:US09376442B2
公开(公告)日:2016-06-28
申请号:US14547938
申请日:2014-11-19
申请人: Takeda GmbH
发明人: Josef Stadlwieser , Beate Schmidt , Heiko Bernsmann , Torsten Dunkern , Ewald Benediktus , Andreas Pahl , Ragna Hussong , Olaf Nimz , Matthias Mueller , Martin Viertelhaus
IPC分类号: A61K31/519 , C07D487/04 , A61P11/00
CPC分类号: C07D487/04 , A61K2300/00
摘要: The compounds of Formula (I), wherein R1, R2, R21, R22, R23, R24, Y and R3 have the meanings as given in the description, the salts thereof, the stereoisomers of the compounds and the salts thereof are effective inhibitors of the type 5 phosphodiesterase and are useful for treating or preventing idiopathic pulmonary lung fibrosis.
摘要翻译: 式(I)化合物,其中R 1,R 2,R 21,R 22,R 23,R 24,Y和R 3具有本说明书中给出的含义,其盐,化合物及其盐的立体异构体是有效的抑制剂 5型磷酸二酯酶,可用于治疗或预防特发性肺部肺纤维化。
-
公开(公告)号:US09340522B2
公开(公告)日:2016-05-17
申请号:US14080881
申请日:2013-11-15
申请人: TAKEDA GMBH
发明人: Imre Schlemminger , Beate Schmidt , Dieter Flockerzi , Hermann Tenor , Christof Zitt , Armin Hatzelmann , Degenhard Marx , Clemens Braun , Raimund Kuelzer , Anke Heuser , Hans-Peter Kley , Geert Jan Sterk
IPC分类号: C07D401/04 , C07D401/14 , C07D405/14 , C07D471/04
CPC分类号: C07D401/04 , C07D401/14 , C07D405/14 , C07D471/04
摘要: The compounds of Formula (I), are novel effective inhibitors of the type 4 phosphodiesterase.
-
公开(公告)号:US09309187B2
公开(公告)日:2016-04-12
申请号:US14397319
申请日:2013-04-30
申请人: TAKEDA GMBH
发明人: Angelika Hoffmeyer , Rainer Boer , Manuela Hessmann , Andreas Pahl , Torsten Dunkern , Simone Hartung , Christof Zitt , Jurgen Volz , Christiane Praechter , Mahindra Makhija , Hiteshkumar Jain , Sandip Gavade , Arati Prabhu , Manojkumar Tiwari , Ashish Keche , Sarvesh Patel
IPC分类号: C07D265/30 , C07C233/81 , C07C233/75 , C07C235/66 , C07C237/40 , C07C237/42 , C07D295/155 , A61K31/196 , A61K31/27 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K45/06 , C07C237/52 , C07C271/42
CPC分类号: C07C233/81 , A61K31/196 , A61K31/27 , A61K31/4453 , A61K31/495 , A61K31/5375 , A61K45/06 , C07C233/75 , C07C235/66 , C07C237/40 , C07C237/42 , C07C237/52 , C07C271/42 , C07D295/155
摘要: The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.
摘要翻译: 其中R1,R4,A和X具有说明书中给出的含义的式(1)化合物是新型有效的EP2激动剂。
-
44.Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors 有权
标题翻译: 羟基-6-杂芳基吩噻嗪及其作为PDE4抑制剂的用途公开(公告)号:US09149479B2
公开(公告)日:2015-10-06
申请号:US14508077
申请日:2014-10-07
申请人: TAKEDA GMBH
发明人: Ulrich Kautz
IPC分类号: C07D211/68 , C07D211/80 , A01N43/42 , A61K31/44 , A61K31/5377 , A61K31/473 , A61K31/506 , A61K31/4985
CPC分类号: A61K31/473 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/04 , C07D417/04 , C07D417/14 , C07D471/04
摘要: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of psoriasis.
摘要翻译: 其中取代基具有说明书中提供的定义的式Ia *****的化合物是可用于治疗牛皮癣的新颖有效的PDE4抑制剂。
-
45.
公开(公告)号:US08758817B2
公开(公告)日:2014-06-24
申请号:US13069584
申请日:2011-03-23
申请人: Rango Dietrich , Isabel Anstett-Klein , Marc Schiller , Hartmut Ney , Manfred Hartmann , Sabine Schäfer-Preuss
发明人: Rango Dietrich , Isabel Anstett-Klein , Marc Schiller , Hartmut Ney , Manfred Hartmann , Sabine Schäfer-Preuss
IPC分类号: A61K9/22
CPC分类号: A61K9/2886 , A61K9/2081 , A61K9/2846 , A61K9/5073 , A61K9/5078 , A61K31/4439
摘要: Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described.
摘要翻译: 描述了用于口服施用(S) - 吡那唑的镁盐的剂型。
-
公开(公告)号:US08754108B2
公开(公告)日:2014-06-17
申请号:US12010124
申请日:2008-01-22
申请人: Rudolf Linder , Rango Dietrich
发明人: Rudolf Linder , Rango Dietrich
IPC分类号: A61K31/4439
CPC分类号: A61K31/4439 , A61K9/0019 , A61K9/19 , A61K47/02 , A61K47/18 , A61K47/183 , Y10S514/925 , Y10S514/926 , Y10S514/927
摘要: Lyophilized pantoprazole preparations which are obtainable by freeze-drying of an aqueous solution of pantoprazole, ethylenediamine tetraacetic acid and/or a suitable salt thereof, and sodium hydroxide and/or sodium carbonate are disclosed. The preparations have advantageous properties when reconstituted for injection.
摘要翻译: 公开了通过冷冻干燥泮托拉唑,乙二胺四乙酸和/或其合适的盐以及氢氧化钠和/或碳酸钠的水溶液获得的冻干泮托拉唑制剂。 当重新配制用于注射时,制剂具有有利的性质。
-
47.NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS 有权
标题翻译: 新型羟基-6-羟基噻嗪类及其作为PDE4抑制剂的用途公开(公告)号:US20140073636A1
公开(公告)日:2014-03-13
申请号:US13873670
申请日:2013-04-30
申请人: TAKEDA GMBH
发明人: Ulrich KAUTZ
IPC分类号: C07D401/04 , C07D401/14 , C07D417/14 , C07D413/04 , C07D405/04
CPC分类号: A61K31/473 , A61K31/4985 , A61K31/501 , A61K31/506 , A61K31/5377 , C07D401/04 , C07D401/14 , C07D405/04 , C07D413/04 , C07D417/04 , C07D417/14 , C07D471/04
摘要: Compounds of the formula Ia***** in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors, useful in the treatment of atopic eczema.
摘要翻译: 其中取代基具有说明书中提供的定义的式Ia *****的化合物是可用于治疗特应性湿疹的新颖有效的PDE4抑制剂。
-
公开(公告)号:US08663694B2
公开(公告)日:2014-03-04
申请号:US11885837
申请日:2006-03-14
CPC分类号: A61K9/1676 , A61K9/0095 , A61K9/1611 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/5042 , A61K9/5078 , A61K31/166 , A61K31/44
摘要: Taste masked dosage forms for oral administration of roflumilast are described.
摘要翻译: 描述了用于口服罗氟司特的口罩剂型。
-
公开(公告)号:US08648100B2
公开(公告)日:2014-02-11
申请号:US11918397
申请日:2006-04-12
申请人: Rolf Beume , Armin Hatzelmann , Degenhard Marx , Christian Schudt , Hermann Tenor , Saadia Eddahibi , Serge Adnot
发明人: Rolf Beume , Armin Hatzelmann , Degenhard Marx , Christian Schudt , Hermann Tenor , Saadia Eddahibi , Serge Adnot
IPC分类号: A61K31/44 , C07D213/74
CPC分类号: A61K31/4412 , A61K31/44 , A61K31/4985 , A61K31/5025 , A61K31/506 , A61K31/519 , A61K31/53
摘要: The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically acceptable salt thereof for the treatment of pulmonary hypertension.
摘要翻译: 本发明涉及罗氟司特,罗氟司特N-氧化物或其药学上可接受的盐用于治疗肺动脉高压的用途。 本发明还涉及Roflumilast,Roflumilast N-氧化物或其药学上可接受的盐与PDE5抑制剂或其药学上可接受的盐的组合用于治疗肺动脉高压的用途。
-
50.Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient 有权
标题翻译: 含有作为活性成分的Pde 4抑制剂和作为赋形剂的聚乙烯吡咯烷酮的口服剂型公开(公告)号:US20130345265A1
公开(公告)日:2013-12-26
申请号:US13874065
申请日:2013-04-30
申请人: Takeda GmbH
发明人: Rango Dietrich , Klaus Eistetter , Hartmut Ney
IPC分类号: A61K31/44
CPC分类号: A61K9/0002 , A61K9/0053 , A61K9/20 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K31/166 , A61K31/44
摘要: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
摘要翻译: 描述了用于口服施用其溶解度小的PDE 4抑制剂的剂型。 它们含有PVP作为粘合剂。
-
-
-
-
-
-
-
-
-